益方生物(688382.SH):D-2570是公司自主研發的一款靶向TYK2的新型口服選擇性抑制劑
格隆匯7月24日丨益方生物(688382.SH)近期在接待機構投資者調研時表示,D-2570是公司自主研發的一款靶向TYK2的新型口服選擇性抑制劑,用於治療銀屑病等自身免疫性疾病。和已獲批上市的施貴寶的氘可來昔替尼一樣,D-2570也是靶向TYK2假激酶結構域的新型抑制劑,希望可以避免產生與JAK1-3抑制劑相關的毒性。根據臨牀前研究數據顯示,D-2570的口服生物利用度較高,在大鼠中並未觀察到與性別相關的PK參數差異,在多次給藥後也未觀察到D-2570的蓄積。D-2570在CD-1小鼠、比格犬和人血漿中均表現出中等程度的蛋白結合率,在SD大鼠血漿中表現出中到高程度的結合,且無明顯濃度依賴性。與在美國獲批上市的氘可來昔替尼片相比,D-2570對JAK1的選擇性更好,因此我們希望在臨牀上會有更大的安全窗口。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.